Medical/Pharmaceuticals
Alterity Therapeutics Announces Publication Demonstrating that ATH434 is Neuroprotective in Animal Model of Parkinsonian Disorder in the Journal of Parkinson's Disease
MELBOURNE, Australia, Jan. 28, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that data in an animal model of Multiple S...
2022-01-28 20:08
2889
"Don't forget leprosy" campaign gathers pace as World Leprosy Day approaches
TOKYO, Jan. 28, 2022 /PRNewswire/ -- Sasakawa Leprosy (Hansen's Disease) Initiative is collaborating with 32 organizations from 13 countries to promote the message "Don't forget leprosy" in the run-up to World Leprosy Day onJanuary 30. The international campaign includes awareness-raising events ...
2022-01-28 19:00
2230
Samsung Biologics reaches agreement with Biogen to acquire full ownership of Samsung Bioepis
* Agreement with Biogen to buyout Biogen's (50% -1 share) stake in Samsung Bioepis Joint Venture for up to USD$2.3 billion * Transaction projected to be accretive to earnings in 2022 and thereafter, fully capitalizing on the high growth potential of Samsung Bioepis * Expected to accelerate g...
2022-01-28 08:10
2655
Ractigen Therapeutics closes an additional $30 million in Series A+ funding to push development of its RNAa platform
NANTONG, China, Jan. 27, 2022 /PRNewswire/ -- Ractigen Therapeutics, a pioneer of the RNAa technology, today announced the closing of a Series A+ financing round totaling$30 million led by SDIC Venture Capital with participation from Eisai Co., Ltd., LC Ventures, CSSD Capital, and Xianghe Capital...
2022-01-27 22:10
2695
I Peace's Cell Manufacturing Facility "Peace Engine Kyoto" now registered as U.S. FDA Drug Establishment
PALO ALTO, Calif., Jan. 26, 2022 /PRNewswire/ -- I Peace, Inc. (CEO: Koji Tanabe ), aPalo Alto-based biotech start-up, announced that its cell manufacturing facility is now listed on the FDA "Drug Establishments Current Registration Site." The registration recognizes I Peace's cell manufacturing f...
2022-01-27 01:00
2084
iMediSync Successfully Launches the Future of Tele-Medicare at CES 2022
SEOUL, South Korea, Jan. 26, 2022 /PRNewswire/ -- iMediSync, A biotech startup
company fromSeoul, South Korea, successfully debuted at CES 2022 to introduce
the new trend of digital healthcare under their motto – Overcome Mental
Pandemic in just 10 Min.
2022-01-26 22:00
4320
China Jo-Jo Drugstores Granted Extension to Meet Nasdaq Minimum Bid Price Requirement
HANGZHOU, China, Jan. 26, 2022 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider inChina, today announced that on J...
2022-01-26 21:00
4736
Adlai Nortye Announces Global License-out Agreement with Biotime for Several Products Including PD-L1 Inhibitor (AN4005) and Anti-hTNFR2 Antibody (AN3025)
NORTH BRUNSWICK, N.J. and HANGZHOU, China, Jan. 26, 2022 /PRNewswire/ -- Adlai Nortye Ltd. ("Adlai Nortye"), a clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies, announced that it has entered into a Global License Agreement with Xiamen Biotime Biot...
2022-01-26 21:00
2262
Hope Medicine Announces US FDA Clearance for Phase II Clinical Trial of A First-in-class Monoclonal Antibody, HMI-115, in Androgen Alopecia
SHANGHAI, Jan. 25, 2022 /PRNewswire/ -- Hope Medicine Inc. ('HopeMed'), a clinical stage innovative biopharmaceutical company, has recently announced that U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for phase II study to evaluate HMI-115, a ...
2022-01-26 08:00
3371
Neurophth Therapeutics' Treatment of Leber's Hereditary Optic Neuropathy Gene Therapy NR082 was Granted Orphan Drug Designation by EMA
WUHAN, China and SAN DIEGO, Jan. 25, 2022 /PRNewswire/ -- Neurophth Therapeutics, Inc., (hereinafter referred to as "Neurophth"), today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) granted the orphan drug designation (ODD) for the Company's le...
2022-01-25 22:00
2423
Daewoong Pharmaceutical Released Positive Phase 3 Topline Results for New Antidiabetic Drug
SEOUL, South Korea, Jan. 25, 2022 /PRNewswire/ -- Daewoong Pharmaceutical (Daewoong) has confirmed promising phase 3 topline results that focuses on the therapeutic effects as an Enavogliflozin monotherapy and a combination therapy with Metformin.Daewoong's Enavogliflozin is an SGLT-2 inhibitor i...
2022-01-25 22:00
2165
KAZIA THERAPEUTICS TO PARTICIPATE IN EDISON GROUP'S GLOBAL HEALTHCARE 'OPEN HOUSE' VIRTUAL CONFERENCE
SYDNEY, Jan. 25, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, DrJames Garner, will be speaking at the Edison Group 'Open House' Event, to be held virtually from25-27 January 2022. Kazia ...
2022-01-25 21:00
3973
Senhwa's Pidnarulex Receives US FDA Fast Track Designation for the Treatment of Solid Tumors with BRCA1/2, PALB2 and other HR Gene Mutations
TAIPEI and SAN DIEGO, Jan. 25, 2022 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced today that the US Food and Drug Administration (FDA) has granted Fast Track...
2022-01-25 20:00
2761
Sequanta selects Olink® Explore 3072 to analyze new cohort study in China
SHANGHAI, Jan. 25, 2022 /PRNewswire/ -- Olink Holding AB (publ) (Nasdaq: OLK) today announced that Sequanta Technologies, a leading multi-omics service provider based inChina, will use Olink® Explore 3072 to analyze the samples to serve a new large scale cohort study in China. Since 2021, Sequa...
2022-01-25 19:36
1844
2022 Japan Prize Laureates Announced
TOKYO, Jan. 25, 2022 /PRNewswire/ -- The Japan Prize Foundation announced the winners of the 2022 Japan prize onJanuary 25. Prof. Katalin Kariko (Hungary/USA ) and Prof.Drew Weissman (USA) are co-winners of the Japan Prize in the field of "Materials and Production," and Prof.Christopher Field (USA...
2022-01-25 14:00
2378
RemeGen's Telitacicept Demonstrates Positive Results in Phase II Trial in Treatment of Primary Sjögren's Syndrome
YANTAI, China, Jan. 24, 2022 /PRNewswire/ -- RemeGen Co., Ltd. (9995.HK), a commercial-ready biotechnology company, recently announced positive results from the completion of its Phase II trial inChina for Telitacicept in the treatment of primary Sjögren's syndrome ("pSS"). A total of 42 patient...
2022-01-25 09:00
4200
ImmVira's New-Generation Vector Poised to Enable CAR-T Treatment for Solid Tumors
SHENZHEN, China, Jan. 24, 2022 /PRNewswire/ -- Demonstrating innovation leadership on a global level, ImmVira announced that, its custom-designed new-generation oncolytic herpes simplex virus ("oHSV") vector enabling CAR-T treatment for solid tumors has started pilot-scale manufacturing and Phar...
2022-01-25 08:30
2081
Kintor Pharma Announced Successful Dosing of the First Patient for Acne Vulgaris Phase II Clinical Trial of KX-826
SUZHOU, China, Jan. 24, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma," HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the first patient dosing in its phase II clinical trial of KX-826("p...
2022-01-24 21:47
3230
MGI's New MGISP-Smart 8 Automated Sample Preparation System Makes International Debut at MEDLAB Middle East
DUBAI, UAE, Jan. 24, 2022 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a global life science leader and innovator, has unveiled its new MGISP-Smart 8 automated sample preparation system to the world at MEDLAB Middle East, which kicked off today at the Dubai World Trade Center. The event marks the ...
2022-01-24 19:30
2075
Samsung Biologics Reports Fourth Quarter & Fiscal Year 2021 Financial Results
* Q4'21 revenue of KRW 444.3 billion increased 18% compared to Q4'20. * Q4'21 operating profit of KRW 128.8 billion increased 39% compared to Q4'20. * FY'21 revenue of KRW 1,568.0 billion, an increase of 35% compared to FY'20. * FY'21 operating profit of KRW 537.3 billion, an increase of 84% ...
2022-01-24 16:25
2859
Week's Top Stories
Most Reposted
Visa redefines its role in travel with the global expansion of Visa Destinations
[Picked up by 336 media titles]
2026-06-30 10:00Sustainable Tourism Academy Celebrates 3,000-User Milestone in First Year with ASEAN Expansion and New Language Support
[Picked up by 323 media titles]
2026-06-29 12:41
Agoda rolls out suite of new features focused on real-time updates and smarter trip planning
[Picked up by 321 media titles]
2026-07-01 10:00
On-us Brings Real-Time Smart E-Vouchers to Google Wallet, Giving Marketers a Live Read on Customer Behavior
[Picked up by 319 media titles]
2026-06-30 11:00
Avnet Brings Ecosystem Together to Scale Edge AI in Singapore
[Picked up by 305 media titles]
2026-06-30 09:00Most Read
JINRO, the World's No. 1 Soju Brand, Partners with V of BTS
2026-07-03 08:00
13922
/UPDATE TO VIDEO -- New York Stock Exchange/
2026-07-01 01:36
7116
NYSE Content Update: Mobility Global Marks First Day as Public Company
2026-07-01 21:22
6371
